Treatment of female pattern hair loss with oral antiandrogens.
4/5 보강
TL;DR
It is shown that female pattern hair loss (FPHL) is either due to androgens or responsive to oral antiandrogen therapy, and this work has potential to help clarify the role of androgens and their role in hair loss.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
spironolactone 200 mg daily and 40 women received cyproterone acetate, either 50 mg daily or 100 mg for 10 days per month if premenopausal
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
High midscalp clinical grade was the only predictor of response identified. A placebo-controlled study is required to compare this outcome to the natural history of FPHL.
📑 코퍼스 인용 관계
· 인용됨 38
📑 인용한 논문 (6) ▾
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation… American journal of clinical dermatology · 2026
- Low Risk of Hypotension in Women Treated with Spironolactone for Hair Loss. Dermatology practical & conceptual · 2025
- Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal w… International journal of women's dermatology · 2025
- Updates in Treatment for Androgenetic Alopecia. Annals of dermatology · 2025
- Th,-e mechanistic insights into the application of retinoids and possible adjunct therapeu… Annals of medicine and surgery (2012) · 2025
- Approaches to management of endocrine therapy-induced alopecia in breast cancer patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
연도별 인용 (2012–2026) · 합계 170
OpenAlex 토픽 ·
Hair Growth and Disorders
Facial Rejuvenation and Surgery Techniques
Breast Implant and Reconstruction
Abstract 🌐 Abstract
[BACKGROUND] It has not been conclusively established that female pattern hair loss (FPHL) is either due to androgens or responsive to oral antiandrogen therapy.
[OBJECTIVES] To evaluate the efficacy of oral antiandrogen therapy in the management of women with FPHL using standardized photographic techniques (Canfield Scientific), and to identify clinical and histological parameters predictive of clinical response.
[METHODS] For this single-centre, before-after, open intervention study, 80 women aged between 12 and 79 years, with FPHL and biopsy-confirmed hair follicle miniaturization [terminal/vellus (T/V) hair ratio < or = 4 : 1] were photographed at baseline and again after receiving a minimum of 12 months of oral antiandrogen therapy. Forty women received spironolactone 200 mg daily and 40 women received cyproterone acetate, either 50 mg daily or 100 mg for 10 days per month if premenopausal. Women using topical minoxidil were excluded. Standardized photographs of the midfrontal and vertex scalp were taken with the head positioned in a stereotactic device. Images were evaluated by a panel of three clinicians experienced in the assessment of FPHL, blinded to patient details and treatment and using a three-point scale.
[RESULTS] As there was no significant difference in the results or the trend between spironolactone and cyproterone acetate the results were combined. Thirty-five (44%) women had hair regrowth, 35 (44%) had no clear change in hair density before and after treatment, and 10 (12%) experienced continuing hair loss during the treatment period. Ordinal logistic regression analysis to identify predictors of response revealed no influence of patient age, menopause status, serum ferritin, serum hormone levels, clinical stage (Ludwig) or histological parameters such as T/V ratio or fibrosis. The only significant predictor was midscalp clinical grade, with higher-scale values associated with a greater response (P = 0.013).
[CONCLUSION] Eighty-eight percent of women receiving oral antiandrogens could expect to see no progression of their FPHL or improvement. High midscalp clinical grade was the only predictor of response identified. A placebo-controlled study is required to compare this outcome to the natural history of FPHL.
[OBJECTIVES] To evaluate the efficacy of oral antiandrogen therapy in the management of women with FPHL using standardized photographic techniques (Canfield Scientific), and to identify clinical and histological parameters predictive of clinical response.
[METHODS] For this single-centre, before-after, open intervention study, 80 women aged between 12 and 79 years, with FPHL and biopsy-confirmed hair follicle miniaturization [terminal/vellus (T/V) hair ratio < or = 4 : 1] were photographed at baseline and again after receiving a minimum of 12 months of oral antiandrogen therapy. Forty women received spironolactone 200 mg daily and 40 women received cyproterone acetate, either 50 mg daily or 100 mg for 10 days per month if premenopausal. Women using topical minoxidil were excluded. Standardized photographs of the midfrontal and vertex scalp were taken with the head positioned in a stereotactic device. Images were evaluated by a panel of three clinicians experienced in the assessment of FPHL, blinded to patient details and treatment and using a three-point scale.
[RESULTS] As there was no significant difference in the results or the trend between spironolactone and cyproterone acetate the results were combined. Thirty-five (44%) women had hair regrowth, 35 (44%) had no clear change in hair density before and after treatment, and 10 (12%) experienced continuing hair loss during the treatment period. Ordinal logistic regression analysis to identify predictors of response revealed no influence of patient age, menopause status, serum ferritin, serum hormone levels, clinical stage (Ludwig) or histological parameters such as T/V ratio or fibrosis. The only significant predictor was midscalp clinical grade, with higher-scale values associated with a greater response (P = 0.013).
[CONCLUSION] Eighty-eight percent of women receiving oral antiandrogens could expect to see no progression of their FPHL or improvement. High midscalp clinical grade was the only predictor of response identified. A placebo-controlled study is required to compare this outcome to the natural history of FPHL.
- p-value P = 0.013
It is shown that female pattern hair loss (FPHL) is either due to androgens or responsive to oral antiandrogen therapy, and this work has potential to help clarify the role of androgens and their role
APA 7
Sinclair, R., Wewerinke, M., & Jolley, D. (2005). Treatment of female pattern hair loss with oral antiandrogens.. The British journal of dermatology, 152(3), 466-73. https://doi.org/10.1111/j.1365-2133.2005.06218.x
Vancouver
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Brit. jour. derm.. 2005;152(3):466-73. doi:10.1111/j.1365-2133.2005.06218.x
AMA 11
Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Brit. jour. derm.. 2005;152(3):466-73. doi:10.1111/j.1365-2133.2005.06218.x
Chicago
Sinclair, R., Wewerinke, M., and Jolley, D.. 2005. "Treatment of female pattern hair loss with oral antiandrogens." The British journal of dermatology 152 (3): 466-73. https://doi.org/10.1111/j.1365-2133.2005.06218.x
MLA 9
Sinclair, R., et al. "Treatment of female pattern hair loss with oral antiandrogens." The British journal of dermatology, vol. 152, no. 3, 2005, pp. 466-73. doi:10.1111/j.1365-2133.2005.06218.x.
PMID
15787815 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Androgenetic Alopecia: Therapy Update.
- Androgenetic Alopecia: An Update of Treatment Options.
- Dermal exosomes containing miR-218-5p promote hair regeneration by regulating β-catenin signaling.
- Female Pattern Hair Loss: a clinical and pathophysiological review.
- Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review.
- Female pattern alopecia: current perspectives.
- The Diagnosis and Treatment of Hair and Scalp Diseases.
- Female pattern hair loss.
- Interventions for female pattern hair loss.
- Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy.
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Dis…
- Female Pattern Hair Loss-An Update.
- The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Sys…
- Female-pattern hair loss: therapeutic update.
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine t…
- Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Mi…
- Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologi…
- An Open-Label Evaluator Blinded Study of the Efficacy and Safety of a New Nutritional Supplement in …
- The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Syste…
같은 제1저자의 인용 많은 논문 (5)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- 피나스테리드가 전립선암 발생에 미치는 영향.
- COVID-19의 50가지 이상의 장기 후유증: 체계적 문헌고찰 및 메타분석.
- 양성 전립선 비대증의 임상적 진행에 대한 doxazosin, finasteride 및 병용 요법의 장기 효과.
- 양성 전립선 비대증 환자에서 finasteride의 효과. The Finasteride Study Group.
- 양성 전립선 비대증 남성에서 급성 요폐의 위험과 수술적 치료 필요성에 대한 finasteride의 효과. Finasteride Long-Term Efficacy and Safety Study Group.
- 원형 탈모에 대한 전장유전체 연관성 연구는 선천면역과 적응면역 모두의 관여를 시사한다.